Does LIFITEGRAST Cause Product packaging quantity issue? 153 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 153 reports of Product packaging quantity issue have been filed in association with LIFITEGRAST (Xiidra). This represents 1.1% of all adverse event reports for LIFITEGRAST.
153
Reports of Product packaging quantity issue with LIFITEGRAST
1.1%
of all LIFITEGRAST reports
0
Deaths
3
Hospitalizations
How Dangerous Is Product packaging quantity issue From LIFITEGRAST?
Of the 153 reports, 3 (2.0%) required hospitalization.
Is Product packaging quantity issue Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LIFITEGRAST. However, 153 reports have been filed with the FAERS database.
What Other Side Effects Does LIFITEGRAST Cause?
Eye irritation (2,486)
Vision blurred (2,465)
Drug ineffective (1,373)
Instillation site pain (1,281)
Dysgeusia (1,067)
Eye pain (1,032)
Instillation site reaction (1,019)
Dry eye (1,013)
Ocular hyperaemia (570)
Lacrimation increased (547)
What Other Drugs Cause Product packaging quantity issue?
LEUPROLIDE (523)
ALBUTEROL (431)
BUDESONIDE\FORMOTEROL (301)
FENTANYL (286)
BUPRENORPHINE (225)
CYCLOSPORINE (206)
ESTRADIOL (201)
BIMATOPROST (177)
RIVAROXABAN (174)
EXENATIDE (154)
Which LIFITEGRAST Alternatives Have Lower Product packaging quantity issue Risk?
LIFITEGRAST vs LIMAPROST
LIFITEGRAST vs LINACLOTIDE
LIFITEGRAST vs LINAGLIPTIN
LIFITEGRAST vs LINAGLIPTIN\METFORMIN
LIFITEGRAST vs LINCOMYCIN